Outlook Therapeutics has stormed back from the brink. The stock closed Friday at $1.58, marking a roughly 479% gain over the past 30 days and a near-tenfold move from its 52-week low of $0.16 in March. In the last two weeks alone, the shares have rallied about 99%. That ferocious run has temporarily eased a Nasdaq compliance threat — but July brings two events that could redefine the company’s trajectory.
The first is a special shareholder meeting on July 16, where three proposals will be voted on: authorizing the issuance of new shares upon exercise of existing warrants, boosting the authorized share count from 260 million to 600 million, and approving a reverse stock split in a range between 1:10 and 1:50. The split is a backstop against delisting — Nasdaq warned the company in February 2026 after the stock traded below $1 for 30 consecutive days. The cure deadline runs to August 17, 2026, requiring at least ten consecutive trading days above $1. If the recent rally fades, the reverse split becomes the last line of defense.
Also on the shareholder agenda is the retroactive approval of a warrant issuance tied to a direct placement from April 2026 that raised $5.0 million gross. If all those warrants — exercisable at $0.31 — are fully exercised, an additional $6.1 million could flow in, subject to the vote.
The real prize, however, hinges on July 29. That is the PDUFA date for the FDA’s decision on ONS-5010, branded as LYTENAVA, a bevacizumab formulation for wet age-related macular degeneration. The FDA classified the resubmitted Biologics License Application as a Class 1 review and is working with the company on final product labeling through an internal dispute resolution process. If approved, LYTENAVA would be the first and only FDA-cleared ophthalmic bevacizumab product with standardized manufacturing and regulated pharmacovigilance — a direct challenge to the estimated 2.7 million off-label bevacizumab injections administered annually in U.S. retinal practices.
Outside the U.S., execution is already under way. LYTENAVA is approved in the European Union and the United Kingdom, and commercial sales have begun in Germany, the U.K., and Austria. A distribution agreement with Mediconsult AG for Switzerland was signed in the second quarter of fiscal 2026, with a launch planned for 2027 pending local marketing authorization. The Netherlands and Ireland are slated to come online later this year, with additional European markets targeted for 2027. In Europe, off-label repackaged bevacizumab accounts for roughly 2.8 million injections annually.
Should investors sell immediately? Or is it worth buying Outlook Therapeutics?
Commercial ambitions clash with a strained balance sheet. Quarterly revenue runs at just under $1.4 million, while net losses come in at about $4.5 million per quarter. EBITDA for the latest quarter was roughly negative $4.4 million. Cash stood at $7.7 million as of March 31, 2026, propped up by ongoing capital measures. The current ratio of 0.5 and negative shareholders’ equity highlight the pressure. In March, Outlook secured $17 million net through a note with Atlas Sciences, carrying an interest rate of the prime rate plus three percentage points, with a floor of 9.5%.
The stock’s volatility reflects the binary nature of the coming weeks. On the last trading day, shares swung between $1.40 and $1.66 — a nearly 19% range. Over the past three months, the stock has been more volatile than 90% of all U.S. equities, with a typical weekly move around 22%. The relative strength index sits at 81.9, firmly in overbought territory.
Three analysts rate the stock a buy. Ascendiant Capital set a $10 price target on June 11. Other analysts peg the speculative fair value in a range of $0.90 to $1.64 per share, heavily dependent on how quickly LYTENAVA could capture U.S. market share. Technical support stands at $1.31 and $0.61.
With the FDA verdict on July 29 and the shareholder vote just 13 days earlier, every signal from the labeling process and every update on European expansion will likely amplify the stock’s already extreme swings. The coming weeks will test whether the rally has been a speculative runup — or the beginning of a new chapter.
Ad
Outlook Therapeutics Stock: Buy or Sell?! New Outlook Therapeutics Analysis from June 21 delivers the answer:
The latest Outlook Therapeutics figures speak for themselves: Urgent action needed for Outlook Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 21.
Outlook Therapeutics: Buy or sell? Read more here...
